Currently, multiple pharmaceutical companies are investigating pan PI3K, isoform-specific PI3K, and dual mTOR/PI3K inhibitors in clinical trials for treating breast cancer, as depicted in Figure 1 [1]. Here, PIK3CB is linked to breast cancer.